Copyright
©The Author(s) 2017.
World J Cardiol. Jun 26, 2017; 9(6): 553-557
Published online Jun 26, 2017. doi: 10.4330/wjc.v9.i6.553
Published online Jun 26, 2017. doi: 10.4330/wjc.v9.i6.553
Ref. | Age/gender | Disease | Administered | Duration of IFN therapy | Mechanism |
Fava et al[4] | 28/NA | CML | IFNα | 13 mo | NA |
Boonen et al[5] | 24/F | CHC | IFNα | 1 mo | Autoimmune |
Wisniewski et al[6] | 42/F | CHC | IFNα | 6 h | Cardio toxicity |
Gressens et al[7] | 40/F | CHC | IFNα2b | 3 mo | Cardio toxicity |
Benjamini et al[8] | 63/M | MM | IFNα2b | 1 mo | Cardio toxicity |
Hamdani et al[9] | 53/F | CHC | PEG IFN α2a | 6 mo | NA |
Nishio et al[10] | 67/M | CHC | PEG IFN 2a | 15 d | Lupus like syndrome |
Popescu et al[11] | 38/F | CHC | PEG IFN 2a | 7 mo | Cardio toxicity |
Ashraf et al[12] | 39/F | MM | IFNα | 1 d | NA |
- Citation: Nishio K, Arase T, Tada H, Tachibana H. Interferon related pericarditis: Review. World J Cardiol 2017; 9(6): 553-557
- URL: https://www.wjgnet.com/1949-8462/full/v9/i6/553.htm
- DOI: https://dx.doi.org/10.4330/wjc.v9.i6.553